Atresia of the urethra is a rare congenital bladder outlet obstruction, a fetal lower urinary tract obstruction (fetal LUTO), that is usually fatal. Unless there is some other egress for the urine to ...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on atresia of the urethra is limited due to the rarity of the condition, which affects fewer than a few hundred individuals worldwide. This low prevalence makes it challenging to conduct systematic clinical studies. Furthermore, the lack of identified genetic factors and established inheritance patterns contributes to the limited understanding of the condition.
The clinical picture of atresia of the urethra includes several significant features. Most commonly, patients experience vesicoureteral reflux and renal insufficiency, both seen in 80-99% of cases. Other notable symptoms include recurrent urinary tract infections (30-79%), megacystis (30-79%), and hydroureter (30-79%). Additionally, conditions such as oligohydramnios, abdominal distention, and bladder fistula may also occur in a significant number of patients.
To navigate the complexities of atresia of the urethra, consider seeking a pediatric urologist or a specialist in congenital urinary tract anomalies. These professionals can provide targeted care and management options. Additionally, exploring clinical trial participation may be beneficial; resources like ClinicalTrials.gov can help identify relevant studies. For further support, the National Organization for Rare Disorders (NORD) offers resources and guidance for families dealing with rare conditions, accessible at rarediseases.org.
Currently, there are no orphan drug designations for atresia of the urethra. However, there is one active clinical trial that may offer hope for patients. You can search for ongoing studies and their details at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=atresia%20of%20urethra. Participation in clinical trials can provide access to new therapies and contribute to the understanding of this condition.
Actionable guidance for navigating care for atresia of urethra
To navigate the complexities of atresia of the urethra, consider seeking a pediatric urologist or a specialist in congenital urinary tract anomalies. These professionals can provide targeted care and management options. Additionally, exploring clinical trial participation may be beneficial; resources like ClinicalTrials.gov can help identify relevant studies. For further support, the National Organization for Rare Disorders (NORD) offers resources and guidance for families dealing with rare conditions, accessible at rarediseases.org.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on atresia of the urethra is limited due to the rarity of the condition, which affects fewer than a few hundred individuals worldwide. This low prevalence makes it challenging to conduct systematic clinical studies. Furthermore, the lack of identified genetic factors and established inheritance patterns contributes to the limited understanding of the condition.
The clinical picture of atresia of the urethra includes several significant features. Most commonly, patients experience vesicoureteral reflux and renal insufficiency, both seen in 80-99% of cases. Other notable symptoms include recurrent urinary tract infections (30-79%), megacystis (30-79%), and hydroureter (30-79%). Additionally, conditions such as oligohydramnios, abdominal distention, and bladder fistula may also occur in a significant number of patients.
To navigate the complexities of atresia of the urethra, consider seeking a pediatric urologist or a specialist in congenital urinary tract anomalies. These professionals can provide targeted care and management options. Additionally, exploring clinical trial participation may be beneficial; resources like ClinicalTrials.gov can help identify relevant studies. For further support, the National Organization for Rare Disorders (NORD) offers resources and guidance for families dealing with rare conditions, accessible at rarediseases.org.
Currently, there are no orphan drug designations for atresia of the urethra. However, there is one active clinical trial that may offer hope for patients. You can search for ongoing studies and their details at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=atresia%20of%20urethra. Participation in clinical trials can provide access to new therapies and contribute to the understanding of this condition.
Actionable guidance for navigating care for atresia of urethra
To navigate the complexities of atresia of the urethra, consider seeking a pediatric urologist or a specialist in congenital urinary tract anomalies. These professionals can provide targeted care and management options. Additionally, exploring clinical trial participation may be beneficial; resources like ClinicalTrials.gov can help identify relevant studies. For further support, the National Organization for Rare Disorders (NORD) offers resources and guidance for families dealing with rare conditions, accessible at rarediseases.org.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on atresia of the urethra is limited due to the rarity of the condition, which affects fewer than a few hundred individuals worldwide. This low prevalence makes it challenging to conduct systematic clinical studies. Furthermore, the lack of identified genetic factors and established inheritance patterns contributes to the limited understanding of the condition.
The clinical picture of atresia of the urethra includes several significant features. Most commonly, patients experience vesicoureteral reflux and renal insufficiency, both seen in 80-99% of cases. Other notable symptoms include recurrent urinary tract infections (30-79%), megacystis (30-79%), and hydroureter (30-79%). Additionally, conditions such as oligohydramnios, abdominal distention, and bladder fistula may also occur in a significant number of patients.
To navigate the complexities of atresia of the urethra, consider seeking a pediatric urologist or a specialist in congenital urinary tract anomalies. These professionals can provide targeted care and management options. Additionally, exploring clinical trial participation may be beneficial; resources like ClinicalTrials.gov can help identify relevant studies. For further support, the National Organization for Rare Disorders (NORD) offers resources and guidance for families dealing with rare conditions, accessible at rarediseases.org.
Currently, there are no orphan drug designations for atresia of the urethra. However, there is one active clinical trial that may offer hope for patients. You can search for ongoing studies and their details at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=atresia%20of%20urethra. Participation in clinical trials can provide access to new therapies and contribute to the understanding of this condition.
Actionable guidance for navigating care for atresia of urethra
To navigate the complexities of atresia of the urethra, consider seeking a pediatric urologist or a specialist in congenital urinary tract anomalies. These professionals can provide targeted care and management options. Additionally, exploring clinical trial participation may be beneficial; resources like ClinicalTrials.gov can help identify relevant studies. For further support, the National Organization for Rare Disorders (NORD) offers resources and guidance for families dealing with rare conditions, accessible at rarediseases.org.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 6, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.